RCT Finds Single-Dose CBD Has No Effect on Brain Chemistry, Cravings, or Drinking in Youth with Alcohol Use Disorder

In a within-subjects, double-blind, placebo-controlled trial of 36 youth (ages 17-22) with AUD, acute 600mg CBD showed no significant effects on anterior cingulate cortex glutamate/glutamine or GABA levels, whole-brain or region-of-interest alcohol cue-reactivity on fMRI, psychophysiological response to alcohol cues (HRV, skin conductance, subjective craving), or alcohol use. No adverse events were observed.

Within-subjects, randomized, double-blind, placebo-controlled design. 36 non-treatment-seeking youth with AUD (69% female, ages 17-22). Multi-modal outcomes including proton MRS, fMRI cue-reactivity, psychophysiological measures, and alcohol use tracking.

Preclinical studies suggested CBD could reduce alcohol use, generating excitement about CBD as a treatment. This first adequately powered human trial in youth found no effects on any outcome, tempering enthusiasm and suggesting chronic administration may be needed.

This null result is important. It suggests that single-dose CBD, despite promising animal data, does not acutely alter the neural or behavioral mechanisms underlying alcohol use disorder in young people. This redirects research toward chronic dosing protocols.

Single acute dose may not capture effects that require chronic administration. Relatively small sample (n = 36). Non-treatment-seeking participants may differ from those motivated to reduce drinking. Within-subjects design controls for individual differences but may introduce order effects.